P&G Focuses On Consumer Health, “Deemphasizes” Pharma
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble says consumer health trends are on its side as the company increases focus on its consumer health business and moves away from pharmaceuticals
You may also be interested in...
P&G Open To M&A Moves, Closed To Board Seat For Activist Investor
P&G posts 2% organic growth in its latest quarter and its adjusted EPS beat analyst expectations as it is again interested in M&A. A few days after releasing its results, company appeals to shareholders to vote against an activist investor's bid for a board seat.
P&G Open To M&A Moves, Closed To Board Seat For Activist Investor
P&G posts 2% organic growth in its latest quarter and its adjusted EPS beat analyst expectations as it is again interested in M&A. A few days after releasing its results, company appeals to shareholders to vote against an activist investor's bid for a board seat.
P&G Throws Weight Behind Consumer Growth After Shedding Pharma
Procter & Gamble faces several options - and some potential challenges - to grow its OTC portfolio using the resources gained in the sale of its prescription drug business